Funding event
The round itself, as filedInferred stageSeed
Sold of offered$2.5M of $4.5M
Filed2026-10-29
Days since filing15
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-10-14
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Landon Bradley NattrassExecutive Officer · Director
- Ryan Thomas Kline NinnessExecutive Officer · Director
- Justin DearbornDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$2.5M of $4.5M sold1 month since first sale
Prior raiseNot flaggedRaised $2.5M against a prior $39K$39K prior raise, filed 2026-10-07
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-10-030
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
All filings
Every filing for this company, newest first, amendments includedAlso raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.